Jacques Cadranel
Overview
Explore the profile of Jacques Cadranel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
305
Citations
7059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbar B, Labreche K, Cadranel J, Veyri M, Morin V, Thiam F, et al.
J Thorac Oncol
. 2025 Feb;
PMID: 39923848
Introduction: NSCLC is frequent and associated with poor prognosis among people living with human immunodeficiency virus (PLWHIV); nevertheless, the contributing factors remain unknown. Methods: We prospectively compared the immunogenomic characteristics...
2.
Ratsihorimanana R, Maitre T, Dusselier M, Triet Ngo M, Mangiapan G, Fournier C, et al.
Eur Respir J
. 2025 Feb;
65(3).
PMID: 39915056
Background: Recurrent respiratory papillomatosis (RRP) is a rare respiratory disease primarily caused by chronic human papillomavirus (HPV) infection of serotypes 6 and 11. It manifests in childhood (juvenile-onset recurrent respiratory...
3.
Liu G, Nyaw S, Mok T, Curcio H, Cortot A, Kam T, et al.
Cancer Med
. 2025 Jan;
14(3):e70369.
PMID: 39861957
Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes....
4.
Mehlman C, Swalduz A, Monnet I, Morin C, Wislez M, Guisier F, et al.
Oncologist
. 2024 Dec;
PMID: 39724403
Introduction: The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges...
5.
Ferreira M, Bejan-Angoulvant T, Marchand-Adam S, Mousset E, Mureau E, Jouneau S, et al.
Respir Med Res
. 2024 Dec;
87:101144.
PMID: 39693827
Introduction: Progressive interstitial lung diseases (ILDs) are rare but severe diseases, with high mortality and morbidity, with no effective pharmacological treatment allowing for long-term remission, and therefore no clear therapeutic...
6.
Sengupta A, Ray A, Upadhyay A, Izumikawa K, Tashiro M, Kimura Y, et al.
Lancet Infect Dis
. 2024 Dec;
25(3):312-324.
PMID: 39617023
Background: Despite antifungal treatment, chronic pulmonary aspergillosis (CPA) is associated with substantial morbidity and mortality. We conducted a systematic review and meta-analysis to evaluate rates of mortality and its predictors...
7.
Birsen G, Gounant V, Girard N, Cadranel J, Monnet I, Raynaud-Donzel C, et al.
Transl Lung Cancer Res
. 2024 Oct;
13(9):2212-2221.
PMID: 39430330
Background: Pulmonary sarcomatoid carcinomas (PSC) are notorious for their poor prognosis and resistance to chemotherapy. The literature suggests that immunotherapy might be effective against this aggressive tumor. This study aims...
8.
Maitre T, Camuset J, Faure M, Cracco C, Maalouf G, Allenbach Y, et al.
Respir Med Case Rep
. 2024 Oct;
52:102106.
PMID: 39364341
A 62-year-old male experienced -MDA5 dermatomyositis with lung involvement, treated with immunosuppressive therapy leading to chronic cavitary pulmonary aspergillosis in left upper lobe. Patient's history was complicated by complete left...
9.
Morin C, Villeneuve T, Norkowski E, Rosencher L, Cadranel J, Mazieres J
Respir Med Res
. 2024 Sep;
86:101138.
PMID: 39288551
No abstract available.
10.
Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R, et al.
Eur Respir J
. 2024 Sep;
64(3.
PMID: 39231630
No abstract available.